Precision Oncology Trends
The latest news on precision oncology research trends.
The analysis also suggested ways to outwit these mechanisms based on the degree of immune cell infiltration into the tumor.
Genetron will provide clinical trial genomic testing and companion diagnostic development services for InnoCare's biomarker-driven oncology drug development.
The study of cancer immunity biomarkers revealed complex immune profiles for most tumors, suggesting the need for customized combinations of immunotherapies.
The groups have written draft recommendations and are now asking for public comment from pathologists and other stakeholders.
Overexpression of immunoproteasome components PSMB8 and PSMB9 were found to be predictive of improved survival and response to immunotherapy.
The high-throughput S2000 sequencer is the second instrument Genetron Health has received NMPA approval for, following the S5 benchtop instrument last year.
Foundation Medicine's liquid biopsy test will be used in the third stage of SCRUM-Japan, which focuses on advanced cancer patientsin Japan and other Asian countries.
The trial will assess vopratelimab and Jounce's PD-1 inhibitor in NSCLC patients, and evaluate the ability of an RNA signature to predict response.
Natera's Signatera test will be used to select and monitor eligible patients with KRAS-mutant tumors who have molecular residual disease after surgery.
Extending a prior agreement with the drugmaker, Personalis will use its DNA/RNA platform to identify both predictive biomarkers and resistance mechanisms.